RANKL drives osteoclast differentiation and activates NF-κB signaling through its receptor RANK, making it indispensable for studying bone remodeling and tumor-associated osteolysis. This tag-free recombinant human TNFSF11 (residues 140–317), expressed in *E. coli*, binds OPG-Fc with a KD of 1.83 pM and RANK-His with a KD below 1 pM in BLI assays, confirming exceptional receptor engagement suitable for osteoclast differentiation assays, NF-κB pathway activation studies, and antibody development campaigns requiring a high-affinity coating antigen or positive control. Endotoxin levels below 1.0 EU/μg minimize LPS-driven artifacts in sensitive immune cell cultures, supporting use in primary monocyte/macrophage osteoclastogenesis models and in vivo tumor biology studies. Purity exceeding 90% by SDS-PAGE, combined with this stringent endotoxin profile, satisfies the quality thresholds commonly required for functional reference standards in RANKL detection assays.
Email: support@cusabio.com
Distributors Worldwide